TransThera Sciences (Nanjing) (J8J) Stock Overview
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
J8J Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
TransThera Sciences (Nanjing), Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.14 |
| 52 Week High | HK$12.20 |
| 52 Week Low | HK$1.00 |
| Beta | 0 |
| 1 Month Change | -63.23% |
| 3 Month Change | -81.31% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| J8J | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.7% | -0.1% | 0.1% |
| 1Y | n/a | 11.4% | -0.5% |
Return vs Industry: Insufficient data to determine how J8J performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how J8J performed against the German Market.
Price Volatility
| J8J volatility | |
|---|---|
| J8J Average Weekly Movement | 20.6% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: J8J's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: J8J's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 123 | Frank Wu | www.transthera.com |
TransThera Sciences (Nanjing), Inc., clinical stage pharmaceutical company company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a multi-kinase inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases.
TransThera Sciences (Nanjing), Inc. Fundamentals Summary
| J8J fundamental statistics | |
|---|---|
| Market cap | €496.95m |
| Earnings (TTM) | -€38.30m |
| Revenue (TTM) | n/a |
Is J8J overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| J8J income statement (TTM) | |
|---|---|
| Revenue | CN¥0 |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥0 |
| Other Expenses | CN¥295.96m |
| Earnings | -CN¥295.96m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did J8J perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/22 18:31 |
| End of Day Share Price | 2026/07/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TransThera Sciences (Nanjing), Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Ming Kong | DBS Bank Ltd |